PriceTargets.com logo

Denali Therapeutics - DNLI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.40
  • Forecasted Upside: 88.34%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$21.45 As of 12/20/2024 06:31 PM ET
▼ -0.04 (-0.19%)

This chart shows the closing price for DNLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Denali Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNLI

Analyst Price Target is $40.40
▲ +88.34% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $40.40, with a high forecast of $90.00 and a low forecast of $26.00. The average price target represents a 88.34% upside from the last price of $21.45.

This chart shows the closing price for DNLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 contributing investment analysts is to moderate buy stock in Denali Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024Stifel NicolausUpgradeHold ➝ Buy$37.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
11/1/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
10/11/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $28.00
10/10/2024Raymond JamesReiterated RatingMarket Perform
10/7/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$35.00 ➝ $35.00
9/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$25.00 ➝ $29.00
9/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
8/5/2024HC WainwrightLower TargetBuy ➝ Buy$95.00 ➝ $90.00
8/2/2024CitigroupBoost TargetBuy ➝ Buy$26.00 ➝ $32.00
8/2/2024WedbushLower TargetOutperform ➝ Outperform$30.00 ➝ $26.00
7/10/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$28.00 ➝ $29.00
5/8/2024WedbushLower TargetOutperform ➝ Outperform$31.00 ➝ $30.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$95.00
5/8/2024Stifel NicolausLower TargetHold ➝ Hold$26.00 ➝ $22.00
4/9/2024UBS GroupLower TargetBuy ➝ Buy$70.00 ➝ $32.00
2/29/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$73.00 ➝ $50.00
2/28/2024HC WainwrightLower TargetBuy ➝ Buy$105.00 ➝ $95.00
2/28/2024WedbushReiterated RatingOutperform ➝ Outperform$31.00
2/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$105.00
12/13/2023CitigroupInitiated CoverageBuy$32.00
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$28.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$31.00
10/24/2023Cantor FitzgeraldReiterated RatingOverweight$85.00 ➝ $35.00
9/6/2023B. RileyInitiated CoverageBuy$38.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$105.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00
8/10/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$85.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$105.00
8/9/2023WedbushLower TargetOutperform ➝ Outperform$37.00 ➝ $31.00
5/9/2023Stifel NicolausLower Target$30.00
4/12/2023Morgan StanleyBoost TargetOverweight$61.00 ➝ $63.00
3/2/2023Stifel NicolausLower Target$36.00 ➝ $32.00
3/2/2023OppenheimerLower TargetOutperform$85.00 ➝ $70.00
3/1/2023Morgan StanleyLower TargetOverweight$65.00 ➝ $61.00
2/28/2023Evercore ISILower TargetOutperform$80.00 ➝ $50.00
2/28/2023WedbushLower TargetOutperform$46.00 ➝ $38.00
2/23/2023HC WainwrightReiterated RatingBuy$105.00
1/30/2023Leerink PartnersReiterated RatingOutperform$50.00
1/30/2023SVB SecuritiesInitiated CoverageOutperform$50.00
1/25/2023Morgan StanleyBoost TargetOverweight$60.00 ➝ $65.00
12/5/2022CowenInitiated CoverageOutperform
12/5/2022CowenInitiated CoverageOutperform
11/8/2022Morgan StanleyLower TargetOverweight$67.00 ➝ $60.00
11/2/2022BTIG ResearchUpgradeNeutral ➝ Buy$38.00
11/2/2022Bank of AmericaInitiated CoverageBuy$40.00
6/23/2022Berenberg BankInitiated CoverageBuy$39.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$99.00 ➝ $82.00
5/6/2022WedbushLower Target$62.00 ➝ $48.00
3/7/2022The Goldman Sachs GroupLower TargetBuy ➝ Buy$114.00 ➝ $98.00
3/1/2022WedbushReiterated RatingOutperform
1/6/2022Morgan StanleyLower TargetOverweight$99.00 ➝ $91.00
11/5/2021Evercore ISIBoost TargetOutperform$70.00 ➝ $111.00
9/20/2021OppenheimerInitiated CoverageOutperform$85.00
9/1/2021Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$78.00
8/16/2021Morgan StanleyLower TargetOverweight$100.00 ➝ $99.00
7/26/2021HC WainwrightReiterated RatingBuy$95.00 ➝ $105.00
7/15/2021HC WainwrightReiterated RatingBuy$95.00
5/18/2021UBS GroupInitiated CoverageBuy$70.00
3/4/2021HC WainwrightBoost TargetBuy$80.00 ➝ $95.00
2/26/2021HC WainwrightReiterated RatingBuy$80.00 ➝ $95.00
2/10/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$105.00
1/8/2021JPMorgan Chase & Co.Initiated CoveragePositive
12/16/2020Morgan StanleyBoost TargetOverweight$75.00 ➝ $100.00
11/11/2020JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$45.00 ➝ $65.00
11/11/2020Morgan StanleyBoost TargetOverweight$45.00 ➝ $75.00
11/10/2020The Goldman Sachs GroupBoost TargetPositive ➝ Buy$61.00 ➝ $81.00
11/6/2020HC WainwrightBoost TargetBuy$45.00 ➝ $65.00
10/16/2020WedbushBoost TargetPositive ➝ Outperform$39.00 ➝ $50.00
10/16/2020BTIG ResearchDowngradeBuy ➝ Neutral
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
8/24/2020Morgan StanleyBoost TargetOverweight$28.00 ➝ $45.00
8/20/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $45.00
8/10/2020WedbushReiterated RatingOutperform
5/13/2020NomuraReiterated RatingBuy$35.00
4/15/2020Morgan StanleyLower TargetOverweight$30.00 ➝ $28.00
3/18/2020Cantor FitzgeraldReiterated RatingNeutral
3/13/2020Evercore ISIUpgradeIn-Line ➝ Outperform$20.00
3/9/2020Nomura SecuritiesReiterated RatingBuy$35.00
2/28/2020WedbushUpgradeNeutral ➝ Outperform$24.00
2/24/2020Jefferies Financial GroupInitiated CoverageBuy$35.00
2/18/2020Stifel NicolausInitiated CoverageHold$26.00
1/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$20.00 ➝ $37.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.20 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 14 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 13 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 24 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 24 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $21.45
Low: $21.00
High: $22.21

50 Day Range

MA: $25.82
Low: $21.43
High: $31.58

52 Week Range

Now: $21.45
Low: $14.56
High: $33.33

Volume

2,810,606 shs

Average Volume

1,062,494 shs

Market Capitalization

$3.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Denali Therapeutics?

The following equities research analysts have issued stock ratings on Denali Therapeutics in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, and Wedbush.
View the latest analyst ratings for DNLI.

What is the current price target for Denali Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Denali Therapeutics in the last year. Their average twelve-month price target is $40.40, suggesting a possible upside of 88.3%. HC Wainwright has the highest price target set, predicting DNLI will reach $90.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $26.00 for Denali Therapeutics in the next year.
View the latest price targets for DNLI.

What is the current consensus analyst rating for Denali Therapeutics?

Denali Therapeutics currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DNLI.

What other companies compete with Denali Therapeutics?

Other companies that are similar to Denali Therapeutics include Neurocrine Biosciences, Bio-Techne, Vaxcyte, Qiagen and Exelixis. Learn More about companies similar to Denali Therapeutics.

How do I contact Denali Therapeutics' investor relations team?

Denali Therapeutics' physical mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (615) 866-8548 and its investor relations email address is [email protected]. The official website for Denali Therapeutics is www.denalitherapeutics.com. Learn More about contacing Denali Therapeutics investor relations.